These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 39273017)
1. PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients. Zhang J; Song Y; Ahn AR; Park HS; Park SH; Moon YJ; Kim KM; Jang KY Cells; 2024 Aug; 13(17):. PubMed ID: 39273017 [TBL] [Abstract][Full Text] [Related]
2. Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells. Li ZF; Yao YD; Zhao YY; Liu Y; Liu ZH; Hu P; Zhu ZR J Clin Lab Anal; 2020 Sep; 34(9):e23362. PubMed ID: 32463132 [TBL] [Abstract][Full Text] [Related]
3. PRG4 represses the genesis and metastasis of osteosarcoma by inhibiting PDL1 expression. Zhang L; Ren H; Wu Y; Xue L; Bai Y; Wei D; Wu Q Tissue Cell; 2024 Jun; 88():102409. PubMed ID: 38781792 [TBL] [Abstract][Full Text] [Related]
4. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma. Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973 [TBL] [Abstract][Full Text] [Related]
5. FAM83H is involved in stabilization of β-catenin and progression of osteosarcomas. Kim KM; Hussein UK; Park SH; Kang MA; Moon YJ; Zhang Z; Song Y; Park HS; Bae JS; Park BH; Ha SH; Moon WS; Kim JR; Jang KY J Exp Clin Cancer Res; 2019 Jun; 38(1):267. PubMed ID: 31215499 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455 [TBL] [Abstract][Full Text] [Related]
7. Interfering with pak4 Protein Expression Affects Osteosarcoma Cell Proliferation and Migration. Fu Y; Fang L; Yin Q; Wu Q; Sui W; Sun Y; Zhao X; Wu Y; Zhou L Biomed Res Int; 2021; 2021():9977001. PubMed ID: 35005025 [TBL] [Abstract][Full Text] [Related]
8. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Zheng B; Ren T; Huang Y; Guo W Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice. Duan XL; Guo JP; Li F; Xiu C; Wang H Future Oncol; 2020 Aug; 16(24):1815-1824. PubMed ID: 32511016 [No Abstract] [Full Text] [Related]
10. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling. Hu T; Fei Z; Su H; Xie R; Chen L Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157 [TBL] [Abstract][Full Text] [Related]
12. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway. Zhang Y; Zhang T; Chen L; Guo Z; Jiang X Aging (Albany NY); 2024 Jun; 16(14):11208-11223. PubMed ID: 39024509 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma. Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018 [TBL] [Abstract][Full Text] [Related]
14. Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis. Li Z; Lu H; Zhang Y; Lv J; Zhang Y; Xu T; Yang D; Duan Z; Guan Y; Jiang Z; Liu K; Liao Y Cancer Sci; 2024 Oct; 115(10):3305-3319. PubMed ID: 39073190 [TBL] [Abstract][Full Text] [Related]
15. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22. Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291 [TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA OIP5-AS1 mediates resistance to doxorubicin by regulating miR-137-3p/PTN axis in osteosarcoma. Sun X; Tian C; Zhang H; Han K; Zhou M; Gan Z; Zhu H; Min D Biomed Pharmacother; 2020 Aug; 128():110201. PubMed ID: 32460190 [TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models. Yati S; Silathapanasakul A; Thakaeng C; Chanasakulniyom M; Songtawee N; Porntadavity S; Pothacharoen P; Pruksakorn D; Kongtawelert P; Yenchitsomanus PT; Chanmee T Cells; 2022 Mar; 11(6):. PubMed ID: 35326493 [TBL] [Abstract][Full Text] [Related]
18. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Keremu A; Aimaiti A; Liang Z; Zou X Cancer Chemother Pharmacol; 2019 Feb; 83(2):255-264. PubMed ID: 30430228 [TBL] [Abstract][Full Text] [Related]
19. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Liu X; He S; Wu H; Xie H; Zhang T; Deng Z Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288 [TBL] [Abstract][Full Text] [Related]
20. Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell. Wang JY; Chen CM; Chen CF; Wu PK; Chen WM Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]